CTIS2023-503948-13-00
Recruiting
Phase 1
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.
aboratorios Farmaceuticos Rovi S.A.0 sites90 target enrollmentMarch 22, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- aboratorios Farmaceuticos Rovi S.A.
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620001261909Ascil Australia Pty LTD16
Completed
Phase 1
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620000108910Ascil Australia Pty Ltd8
Completed
Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesACTRN12620001019998Gilead Sciences50
Active, not recruiting
Not Applicable
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32
Completed
Phase 1
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisRespiratory - Other respiratory disorders / diseasesACTRN12620001141932Avalyn Pharma Pty Ltd38